All patent litigation between IntelGenx (TSXV:IGX; OTCQX:IGXT), Par Pharmaceutical, Indivior and Indivior UK, and Aquestive Therapeutics (formerly MonoSol Rx) related to Suboxone film has been settled.
The accord permits Par to begin selling a generic version of Suboxone film on Jan. 1, 2023, or earlier under certain circumstances. Par is IntelGenx’s commercial and development partner for a generic version of Suboxone sublingual film product, which is indicated for the treatment of opioid dependence.
“We are very pleased with this outcome,” Dr. Horst Zerbe, president and CEO of IntelGenx, said in a statement. According to IMS data, the oral film market for opioid dependence in the U.S. was worth more than $1.8-billion in 2017. “That is undoubtedly larger today as the opioid abuse epidemic has continued to grow,” he added.
